Sovran Advisors LLC Purchases New Shares in Celldex Therapeutics, Inc. $CLDX

Key Points

• Sovran Advisors LLC acquired 39,476 shares of Celldex Therapeutics, valued at approximately $842,000, representing a 0.06% ownership stake in the company.
• Celldex Therapeutics' stock opened at $25.92 and has fluctuated between a twelve month low of $14.40 and a high of $47.00, with a current market capitalization of $1.72 billion.
• Equities analysts have a consensus rating of "Moderate Buy" for Celldex Therapeutics, with target prices ranging from $38.00 to $62.00.

Sovran Advisors LLC acquired a new stake in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 39,476 shares of the biopharmaceutical company's stock, valued at approximately $842,000. Sovran Advisors LLC owned approximately 0.06% of Celldex Therapeutics at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of CLDX. Mirador Capital Partners LP boosted its holdings in Celldex Therapeutics by 24.1% in the 2nd quarter. Mirador Capital Partners LP now owns 158,717 shares of the biopharmaceutical company's stock valued at $3,230,000 after purchasing an additional 30,843 shares during the period. PDT Partners LLC purchased a new stake in shares of Celldex Therapeutics in the 1st quarter valued at about $379,000. Trexquant Investment LP bought a new stake in shares of Celldex Therapeutics during the 1st quarter valued at about $1,420,000. Deutsche Bank AG increased its position in shares of Celldex Therapeutics by 13.8% in the first quarter. Deutsche Bank AG now owns 138,289 shares of the biopharmaceutical company's stock worth $2,510,000 after purchasing an additional 16,788 shares during the last quarter. Finally, Two Sigma Investments LP bought a new position in shares of Celldex Therapeutics in the fourth quarter worth approximately $835,000.

Celldex Therapeutics Stock Up 1.0%

Shares of Celldex Therapeutics stock traded up $0.25 on Monday, hitting $24.86. The stock had a trading volume of 1,012,689 shares, compared to its average volume of 1,415,654. Celldex Therapeutics, Inc. has a one year low of $14.40 and a one year high of $47.00. The stock's 50-day simple moving average is $23.05 and its two-hundred day simple moving average is $20.92. The stock has a market cap of $1.65 billion, a price-to-earnings ratio of -8.26 and a beta of 1.19.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($0.85) earnings per share for the quarter, beating the consensus estimate of ($0.86) by $0.01. The business had revenue of $0.73 million during the quarter, compared to analysts' expectations of $1.13 million. Celldex Therapeutics had a negative net margin of 3,446.88% and a negative return on equity of 27.61%. As a group, equities analysts predict that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Wall Street Analyst Weigh In

CLDX has been the subject of several research analyst reports. HC Wainwright dropped their target price on shares of Celldex Therapeutics from $50.00 to $42.00 and set a "buy" rating for the company in a research report on Wednesday, August 20th. Wells Fargo & Company dropped their price objective on shares of Celldex Therapeutics from $44.00 to $38.00 and set an "overweight" rating for the company in a report on Wednesday, August 20th. Canaccord Genuity Group reissued a "buy" rating and issued a $62.00 target price on shares of Celldex Therapeutics in a research note on Wednesday, September 17th. Finally, Citigroup dropped their price target on Celldex Therapeutics from $56.00 to $48.00 and set a "buy" rating for the company in a research note on Wednesday, August 20th. Seven analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, Celldex Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $46.67.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.